INSIGHTS ON UPSTREAM MANUFACTURING
-
![GettyImages-2193144544-scientist-cell-culture-in-lab]( "Human Derived Cell Substrate Characterization")
Human Derived Cell Substrate CharacterizationSafe human cell line use needs key safety, identity, and purity testing steps at each cell bank stage. Robust assay plans assure full regulatory compliance, high safety, and product quality.
-
![GettyImages-1087219526-scientist-computer-screen-compliance-sterilization]( "Monoclonal Antibody Lot Release Testing For CHO Cell–Derived Products")
Monoclonal Antibody Lot Release Testing For CHO Cell–Derived ProductsBiologic lot testing spans bulk harvest to final stability. Core panels check purity, safety, identity, and potency to ensure compliance, low risk, and high product quality across production.
-
![GettyImages-1411964582-scientist-microscope-testing-food-quality]( "CHO Cell Line Characterization")
CHO Cell Line CharacterizationBiologic lot testing spans bulk harvest to final stability. Core panels check purity, safety, identity, and potency to ensure compliance, low risk, and high product quality across production.
-
![GettyImages-2193144544-scientist-cell-culture-in-lab]( "Support A Biosimilar Program From Cell Line Development To Commercial")
Support A Biosimilar Program From Cell Line Development To CommercialExplore end-to-end biosimilar development, combining proven commercial experience, integrated CMC expertise, and seamless GMP manufacturing to accelerate regulatory and commercial success.
-
CLD Case Study: Complex Biologics – Bispecific Fusion Nanobody7/17/2026
See how a bispecific fusion nanobody (BFN) achieved BsAb titers above 7 g/L with 5 of 6 clones stable beyond 60 generations — from CLD through cGMP manufacturing.
-
Platform Strategy For Improving Manufacturability And Efficacy In Bispecific Antibodies7/15/2026
Novel bispecific antibody engineering overcomes assembly and manufacturability challenges, enabling scalable production while preserving therapeutic function, stability, purity, and product quality.
-
Leveraging 3Rs For Superior Cell Line Characterization7/13/2026
Explore how non-animal methods, including next generation sequencing, are advancing biologics safety testing through the 3Rs while supporting faster adventitious virus testing and more.
-
Production Of Disulfide-Rich Cow Knob Domain Antibodies7/8/2026
Discover how a microbial expression platform enabled high-titer production of disulfide-rich bovine knob domain antibodies with confirmed SARS-CoV-2 spike protein binding activity at 19 nM IC50.
UPSTREAM MANUFACTURING SOLUTIONS
-
![pharma-development-GettyImages-2166352610]( "Powering Possibilities In Early Phase Development")
Streamline early biologics development by combining model-guided sequence selection with parallel scale-up strategies to overcome cell line unpredictability and reduce tech transfer risks.
-
![GettyImages-2258800592-car-t-cell-therapy-manufacturing-3d]( "Enabling Flexibility For T Cell Isolation And Activation Using Workflows")
Modular manufacturing strategies can support scalable T-cell processing while maintaining key quality measures. Explore how workflow design choices can help balance efficiency and performance.
-
![cell culture, medicine, medical, laboratory-GettyImages-1491010530]( "Consistone Yeast Extract UF: Batch Versus Fed-Batch Processing")
Gain insight into how targeted nutrient supplementation increased CHO cell growth, boosted antibody production, and improved glycosylation profiles across batch and fed-batch cultures.
-
![GettyImages-1002000796-lab-research-scientist-development]( "From Cell Line To Clinic: 4 Months Sooner With mAb Accelerator")
Launch cell line development during funding to save four months, beating early bottlenecks and reducing capital risk with milestone-aligned models.
-
![GettyImages-2193144544-scientist-cell-culture-in-lab]( "Efficient CLD For Complex Biologics And High-Titer mAbs")
We aren't just a CDMO for standard antibodies, we also specialize in taking on the complex molecules (bispecifics, trispecifics, FC-fusions, and more).
